Pyxis Oncology, Inc.
Pyxis Oncology, Inc. scores highest on Anchor (47) and lowest on Price (3). Its PosiPenta is 27.64 out of 100, weaker than most similar companies.
On the Penta Grid this week, Pyxis Oncology, Inc. is Grid #789 of 837 in the Healthcare sector in United States, and Grid #3,725 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. | 27.64 | 3 | 39 | 35 | 15 | 47 |
| Alector, Inc. | 34.46 | 0 | 46 | 57 | 12 | 57 |
| Pro-Dex, Inc. | 64.12 | 54 | 54 | 79 | 64 | 70 |
| Protalix BioTherapeutics, Inc. | 66.10 | 62 | 83 | 82 | 71 | 33 |
| RxSight, Inc. | 45.37 | 43 | 48 | 24 | 64 | 47 |
| Glass House Brands Inc. | 41.38 | 16 | 71 | 19 | 47 | 55 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.20 |
| P/B ratio | 17.54 |
EEarnings
| Trailing EPS | ₹-132.60 |
| Forward EPS | ₹-104.92 |
NNitro
| Price | 159.12 |
| 52-week high | 525.67 |
| 52-week low | 97.56 |
| Fall from 52-week high | 69.7% |
TTorque
| Return on equity (ROE) | -179.10% |
| Debt-to-equity | 1.56 |
AAnchor
| Beta (price swings) | 1.38 |
| Market cap | ₹1,900 Cr |
| Insider holding | 9.47% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Pyxis Oncology, Inc.'s PosiPenta score?
Pyxis Oncology, Inc.'s PosiPenta is 27.64 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Pyxis Oncology, Inc. stand on the Penta Grid?
On the Penta Grid this week, Pyxis Oncology, Inc. is Grid #789 of 837 in the Healthcare sector in United States, and Grid #3,725 of 4,000 in United States.
Which PosiPenta pillar is strongest for Pyxis Oncology, Inc.?
Anchor (stability and dividends), with a score of 47 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Pyxis Oncology, Inc.?
Price (valuation), with a score of 3 out of 100: much weaker than most similar companies.
Has Pyxis Oncology, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.80 points, from 23.84 to 27.64.
PositoAI is for research and education only and is not investment advice.